Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a Human Immunodeficiency Virus type 1 chimeric virus

Riri Shibata, Christine Siemon, Susan C. Czajak, Ronald Charles Desrosiers, Malcolm A. Martin

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Three rhesus macaques, previously immunized with SIVΔ3 or SIVΔ2, each an attenuated derivative of SIV(mac239), and two naive monkeys were challenged with 30,000 50% tissue culture infective doses of SHIV, an SIV/human immunodeficiency virus type 1 (HIV-1) chimeric virus bearing the dual-tropic envelope of HIV-1(DH12). By several criteria, including virus isolation, serological assays, and PCR (both DNA and reverse transcriptase), SHIV levels were reduced to barely detectable levels in the circulating blood of vaccinated animals. The resistant SIV-vaccinated macaques had no preexisting neutralizing antibodies directed against SHIV, nor did they produce neutralizing antibodies at any time over a 14-month observation period following SHIV challenge. Interestingly, SIV sequences, derived from the vaccine, could be amplified from numerous tissue samples collected at the conclusion of the experiment, 60 weeks postchallenge, but SHIV-specific sequences (viz, HIV-1 env) could not. These results demonstrate that live attenuated SIV vaccines provide strong long-term protection even against challenge strains with highly divergent envelope sequences.

Original languageEnglish (US)
Pages (from-to)8141-8148
Number of pages8
JournalJournal of Virology
Volume71
Issue number11
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Human immunodeficiency virus 1
HIV-1
Vaccines
live vaccines
vaccines
Viruses
Neutralizing Antibodies
neutralizing antibodies
viruses
SAIDS Vaccines
Attenuated Vaccines
RNA-directed DNA polymerase
RNA-Directed DNA Polymerase
Macaca
Macaca mulatta
Haplorhini
monkeys
tissue culture

ASJC Scopus subject areas

  • Immunology

Cite this

Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a Human Immunodeficiency Virus type 1 chimeric virus. / Shibata, Riri; Siemon, Christine; Czajak, Susan C.; Desrosiers, Ronald Charles; Martin, Malcolm A.

In: Journal of Virology, Vol. 71, No. 11, 11.1997, p. 8141-8148.

Research output: Contribution to journalArticle

@article{6ca6abfba6e74677a988de2f388024bd,
title = "Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a Human Immunodeficiency Virus type 1 chimeric virus",
abstract = "Three rhesus macaques, previously immunized with SIVΔ3 or SIVΔ2, each an attenuated derivative of SIV(mac239), and two naive monkeys were challenged with 30,000 50{\%} tissue culture infective doses of SHIV, an SIV/human immunodeficiency virus type 1 (HIV-1) chimeric virus bearing the dual-tropic envelope of HIV-1(DH12). By several criteria, including virus isolation, serological assays, and PCR (both DNA and reverse transcriptase), SHIV levels were reduced to barely detectable levels in the circulating blood of vaccinated animals. The resistant SIV-vaccinated macaques had no preexisting neutralizing antibodies directed against SHIV, nor did they produce neutralizing antibodies at any time over a 14-month observation period following SHIV challenge. Interestingly, SIV sequences, derived from the vaccine, could be amplified from numerous tissue samples collected at the conclusion of the experiment, 60 weeks postchallenge, but SHIV-specific sequences (viz, HIV-1 env) could not. These results demonstrate that live attenuated SIV vaccines provide strong long-term protection even against challenge strains with highly divergent envelope sequences.",
author = "Riri Shibata and Christine Siemon and Czajak, {Susan C.} and Desrosiers, {Ronald Charles} and Martin, {Malcolm A.}",
year = "1997",
month = "11",
language = "English (US)",
volume = "71",
pages = "8141--8148",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a Human Immunodeficiency Virus type 1 chimeric virus

AU - Shibata, Riri

AU - Siemon, Christine

AU - Czajak, Susan C.

AU - Desrosiers, Ronald Charles

AU - Martin, Malcolm A.

PY - 1997/11

Y1 - 1997/11

N2 - Three rhesus macaques, previously immunized with SIVΔ3 or SIVΔ2, each an attenuated derivative of SIV(mac239), and two naive monkeys were challenged with 30,000 50% tissue culture infective doses of SHIV, an SIV/human immunodeficiency virus type 1 (HIV-1) chimeric virus bearing the dual-tropic envelope of HIV-1(DH12). By several criteria, including virus isolation, serological assays, and PCR (both DNA and reverse transcriptase), SHIV levels were reduced to barely detectable levels in the circulating blood of vaccinated animals. The resistant SIV-vaccinated macaques had no preexisting neutralizing antibodies directed against SHIV, nor did they produce neutralizing antibodies at any time over a 14-month observation period following SHIV challenge. Interestingly, SIV sequences, derived from the vaccine, could be amplified from numerous tissue samples collected at the conclusion of the experiment, 60 weeks postchallenge, but SHIV-specific sequences (viz, HIV-1 env) could not. These results demonstrate that live attenuated SIV vaccines provide strong long-term protection even against challenge strains with highly divergent envelope sequences.

AB - Three rhesus macaques, previously immunized with SIVΔ3 or SIVΔ2, each an attenuated derivative of SIV(mac239), and two naive monkeys were challenged with 30,000 50% tissue culture infective doses of SHIV, an SIV/human immunodeficiency virus type 1 (HIV-1) chimeric virus bearing the dual-tropic envelope of HIV-1(DH12). By several criteria, including virus isolation, serological assays, and PCR (both DNA and reverse transcriptase), SHIV levels were reduced to barely detectable levels in the circulating blood of vaccinated animals. The resistant SIV-vaccinated macaques had no preexisting neutralizing antibodies directed against SHIV, nor did they produce neutralizing antibodies at any time over a 14-month observation period following SHIV challenge. Interestingly, SIV sequences, derived from the vaccine, could be amplified from numerous tissue samples collected at the conclusion of the experiment, 60 weeks postchallenge, but SHIV-specific sequences (viz, HIV-1 env) could not. These results demonstrate that live attenuated SIV vaccines provide strong long-term protection even against challenge strains with highly divergent envelope sequences.

UR - http://www.scopus.com/inward/record.url?scp=0030765973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030765973&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 8141

EP - 8148

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

ER -